Skip to content
2000
Volume 16, Issue 9
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Human serum albumin (HSA) is the most abundant protein in the plasma. HSA plays a central role in drug pharmacokinetics because most drugs bound to HSA are delivered to their target organ/tissues. The prodrug strategies have shown great promise for improving the activity and selectivity of drugs. Designing prodrugs based on special HSA residues, such as Cys34 and Lys residues, has been extensively studied. Therefore, this review provides an overview of the development of nonsteroidal anti-inflammatory and anticancer prodrugs based on these special residues. In conclusion, this review may guide the rational design and development of new prodrugs for future clinical applications.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026615666150825142908
2016-04-01
2025-06-14
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026615666150825142908
Loading

  • Article Type:
    Research Article
Keyword(s): Drug design; Human serum albumin; Prodrug; Protein structure
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test